FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034504732> ?p ?o ?g. }

• W2034504732 endingPage "1035.e3" @default.
• W2034504732 startingPage "1027" @default.
• W2034504732 abstract "Purpose To investigate the expression, release, and proteolytic degradation of galectin-3 in patients with dry eye disease. Design Observational case series with a comparison group. Methods Tear washes and conjunctival impression cytology specimens were collected through standard procedures from 16 patients with dry eye and 11 age-matched healthy subjects. Galectin-3 content in tears was analyzed by quantitative Western blot, using recombinant galectin-3 protein to generate a calibration curve. The relative expression of galectin-3 and matrix metalloproteinase 9 (MMP9) was evaluated by quantitative polymerase chain reaction. The cleavage of galectin-3 was studied in vitro using activated recombinant MMP9 and protease inhibitors. Results The concentration of galectin-3 protein in tears, but not galectin-3 expression in conjunctival epithelium, was significantly higher in tears of patients with dry eye (0.38 ng/μg total protein, range 0.04–1.36) compared to healthy subjects (0.12 ng/μg total protein, range 0.00–0.41) (P < .01). By Western blot, an intact (∼28.0 kDa) galectin-3 band was identified in tear samples from healthy subjects, whereas 50% of the dry eye samples were characterized by the additional presence of a partially degraded form (∼25.4 kDa). In our experiments, elevated expression of MMP9 in dry eye subjects correlated with the ability of active MMP9 to cleave galectin-3 from recombinant origin. Interestingly, cleavage of endogenous galectin-3 in tear samples was impaired using a broad-spectrum proteinase inhibitor cocktail, but not the pan-specific MMP inhibitor GM6001, suggesting the presence of proteases other than MMPs in promoting galectin-3 degradation in dry eye. Conclusions Our results indicate that release of cellular galectin-3 into tears is associated with epithelial dysfunction in dry eye, and that galectin-3 proteolytic cleavage may contribute to impaired ocular surface barrier function. To investigate the expression, release, and proteolytic degradation of galectin-3 in patients with dry eye disease. Observational case series with a comparison group. Tear washes and conjunctival impression cytology specimens were collected through standard procedures from 16 patients with dry eye and 11 age-matched healthy subjects. Galectin-3 content in tears was analyzed by quantitative Western blot, using recombinant galectin-3 protein to generate a calibration curve. The relative expression of galectin-3 and matrix metalloproteinase 9 (MMP9) was evaluated by quantitative polymerase chain reaction. The cleavage of galectin-3 was studied in vitro using activated recombinant MMP9 and protease inhibitors. The concentration of galectin-3 protein in tears, but not galectin-3 expression in conjunctival epithelium, was significantly higher in tears of patients with dry eye (0.38 ng/μg total protein, range 0.04–1.36) compared to healthy subjects (0.12 ng/μg total protein, range 0.00–0.41) (P < .01). By Western blot, an intact (∼28.0 kDa) galectin-3 band was identified in tear samples from healthy subjects, whereas 50% of the dry eye samples were characterized by the additional presence of a partially degraded form (∼25.4 kDa). In our experiments, elevated expression of MMP9 in dry eye subjects correlated with the ability of active MMP9 to cleave galectin-3 from recombinant origin. Interestingly, cleavage of endogenous galectin-3 in tear samples was impaired using a broad-spectrum proteinase inhibitor cocktail, but not the pan-specific MMP inhibitor GM6001, suggesting the presence of proteases other than MMPs in promoting galectin-3 degradation in dry eye. Our results indicate that release of cellular galectin-3 into tears is associated with epithelial dysfunction in dry eye, and that galectin-3 proteolytic cleavage may contribute to impaired ocular surface barrier function." @default.
• W2034504732 created "2016-06-24" @default.
• W2034504732 creator A5010663780 @default.
• W2034504732 creator A5013431023 @default.
• W2034504732 creator A5021687613 @default.
• W2034504732 creator A5027798711 @default.
• W2034504732 creator A5058633652 @default.
• W2034504732 creator A5058971301 @default.
• W2034504732 creator A5074998414 @default.
• W2034504732 creator A5075922848 @default.
• W2034504732 date "2015-06-01" @default.
• W2034504732 modified "2023-10-18" @default.
• W2034504732 title "Alteration of Galectin-3 in Tears of Patients With Dry Eye Disease" @default.
• W2034504732 cites W15541802 @default.
• W2034504732 cites W1969005800 @default.
• W2034504732 cites W1974126299 @default.
• W2034504732 cites W1974613273 @default.
• W2034504732 cites W1979487024 @default.
• W2034504732 cites W198570261 @default.
• W2034504732 cites W1985965035 @default.
• W2034504732 cites W1993362861 @default.
• W2034504732 cites W2005490742 @default.
• W2034504732 cites W2014207594 @default.
• W2034504732 cites W2016967911 @default.
• W2034504732 cites W2024909241 @default.
• W2034504732 cites W2025886211 @default.
• W2034504732 cites W2044434705 @default.
• W2034504732 cites W2046206159 @default.
• W2034504732 cites W2051146429 @default.
• W2034504732 cites W2056060554 @default.
• W2034504732 cites W2068160105 @default.
• W2034504732 cites W2069883829 @default.
• W2034504732 cites W2073775017 @default.
• W2034504732 cites W2074357311 @default.
• W2034504732 cites W2074443029 @default.
• W2034504732 cites W2084881844 @default.
• W2034504732 cites W2094188666 @default.
• W2034504732 cites W2113085046 @default.
• W2034504732 cites W2116396800 @default.
• W2034504732 cites W2125369556 @default.
• W2034504732 cites W2125827155 @default.
• W2034504732 cites W2128890658 @default.
• W2034504732 cites W2129689791 @default.
• W2034504732 cites W2146634463 @default.
• W2034504732 cites W2150173080 @default.
• W2034504732 cites W2150954587 @default.
• W2034504732 cites W2157903759 @default.
• W2034504732 cites W2164471400 @default.
• W2034504732 cites W2170252526 @default.
• W2034504732 cites W36552519 @default.
• W2034504732 doi "https://doi.org/10.1016/j.ajo.2015.02.008" @default.
• W2034504732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4426220" @default.
• W2034504732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25703476" @default.
• W2034504732 hasPublicationYear "2015" @default.
• W2034504732 type Work @default.
• W2034504732 sameAs 2034504732 @default.
• W2034504732 citedByCount "40" @default.
• W2034504732 countsByYear W20345047322015 @default.
• W2034504732 countsByYear W20345047322016 @default.
• W2034504732 countsByYear W20345047322017 @default.
• W2034504732 countsByYear W20345047322018 @default.
• W2034504732 countsByYear W20345047322019 @default.
• W2034504732 countsByYear W20345047322020 @default.
• W2034504732 countsByYear W20345047322021 @default.
• W2034504732 countsByYear W20345047322022 @default.
• W2034504732 countsByYear W20345047322023 @default.
• W2034504732 crossrefType "journal-article" @default.
• W2034504732 hasAuthorship W2034504732A5010663780 @default.
• W2034504732 hasAuthorship W2034504732A5013431023 @default.
• W2034504732 hasAuthorship W2034504732A5021687613 @default.
• W2034504732 hasAuthorship W2034504732A5027798711 @default.
• W2034504732 hasAuthorship W2034504732A5058633652 @default.
• W2034504732 hasAuthorship W2034504732A5058971301 @default.
• W2034504732 hasAuthorship W2034504732A5074998414 @default.
• W2034504732 hasAuthorship W2034504732A5075922848 @default.
• W2034504732 hasBestOaLocation W20345047322 @default.
• W2034504732 hasConcept C104317684 @default.
• W2034504732 hasConcept C109523444 @default.
• W2034504732 hasConcept C126322002 @default.
• W2034504732 hasConcept C142724271 @default.
• W2034504732 hasConcept C151730666 @default.
• W2034504732 hasConcept C153911025 @default.
• W2034504732 hasConcept C175156509 @default.
• W2034504732 hasConcept C185592680 @default.
• W2034504732 hasConcept C203014093 @default.
• W2034504732 hasConcept C2776415932 @default.
• W2034504732 hasConcept C2778275304 @default.
• W2034504732 hasConcept C40767141 @default.
• W2034504732 hasConcept C43369102 @default.
• W2034504732 hasConcept C55493867 @default.
• W2034504732 hasConcept C71924100 @default.
• W2034504732 hasConcept C85265743 @default.
• W2034504732 hasConcept C86803240 @default.
• W2034504732 hasConceptScore W2034504732C104317684 @default.
• W2034504732 hasConceptScore W2034504732C109523444 @default.
• W2034504732 hasConceptScore W2034504732C126322002 @default.
• W2034504732 hasConceptScore W2034504732C142724271 @default.
• W2034504732 hasConceptScore W2034504732C151730666 @default.

• next